EVALUATION OF DAPANSUTRILE AGAINST PALMITATE-INDUCED NLRP3 INFLAMMASOME ACTIVATION AND INSULIN RESISTANCE IN 3T3-L1 ADIPOCYTES
Abstract
Objective: Palmitate (PA)-induced lipid stress activates the NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome and disrupts insulin signaling in adipocytes. This study evaluated the protective effects of dapansutrile (DAPA) against PA-induced inflammasome activation and insulin resistance in differentiated 3T3-L1 adipocytes. Methods: Differentiated 3T3-L1 adipocytes were exposed to PA and treated with DAPA at 1, 5, or 10 μM. DAPA alone and MCC950 were included as treatment and pharmacological controls. Cell viability, insulin-stimulated 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino)-2-deoxyglucose uptake, interleukin-1beta (IL-1β) secretion, oxidative stress, lipid handling, and adipokine release were assessed. Gene expression was examined using reverse transcription quantitative real-time polymerase chain reaction, while inflammasome-associated and insulin-signaling proteins were evaluated by Western blotting. Results: PA reduced cell viability and glucose uptake to 78.4% and 55.2% of control, respectively, and increased IL-1β secretion to 82.6 pg/mL (p<0.05). It increased the relative expression of Nlrp3, Pycard, Casp1, Il1b, and Il18, while reducing Irs1, Slc2a4, and Adipoq. DAPA produced concentration-dependent improvements in inflammatory, oxidative, and metabolic parameters. At 10 μM, viability and glucose uptake approached control values at 94.1% and 89.1%, respectively, while IL-1β declined to 30.8 pg/mL (p<0.05 vs. PA). Protein analysis indicated reduced inflammasome activation together with improved AKT and AS160 phosphorylation and membrane glucose transporter Type 4 expression. Conclusion: DAPA attenuated PA-induced inflammatory activation and improved insulin signaling in 3T3-L1 adipocytes, supporting further investigation of adipocyte NLRP3 inhibition in metabolic inflammation.